Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
海角七号
发表于 2024-3-7 11:10:54
237
0
0
On March 6th local time, the US Food and Drug Administration (FDA) approved Pfizer's BESPONSA& Reg; (Oxytozumab) is used to treat children aged 1 year and above with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
